SMStephen P. Mulligan

Stephen P. Mulligan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen P. Mulligan has a total of 361 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

    by Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, et al.

    Summary: Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of 2 years of daily lenalidomide maintenance versus observation in patients with CLL and residual disease after initial immunochemotherapy. The primary end‐point was time to disease progression or death from randomisation. Between May 2011 and January 2018, 143 patients were randomised to receive lenalidomide ( n = 71) or observation ( n = 72). Median progression‐free survival (PFS) was longer with lenalidomide at 64.6 months (95% confidence interval [CI] 47.7 to not reached) versus 42.4 months (95% CI 32.3–61.6) in the observation arm ( p = 0.039). Lenalidomide benefit persisted for 3 years after maintenance cessation. There was no difference in overall survival. More patients taking lenalidomide achieved MRD negativity, especially those who received at least 20 maintenance cycles. Lenalidomide led to more cytopenias, infections and gastrointestinal effects. There were no cases of acute lymphoblastic leukaemia. In patients with CLL selected by the presence of residual disease at the end of initial chemoimmunotherapy, lenalidomide maintenance increased the chance of achieving MRD negativity and prolonged PFS.

  • Open Access

    Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

    by Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, et al.

    In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management. This paper provides an expert consensus update to the 2023 statement, offering current, regionally relevant guidance on the diagnosis, risk stratification and management of CLL, including treatment selection, sequencing of therapy, management of complications and supportive care. Recommendations were developed through a structured consensus process involving Australian and New Zealand clinicians with expertise in CLL and are endorsed by the Australasian Lymphoma Alliance, the Australasian Leukaemia and Lymphoma Group CLL Working Party and the Haematology Society of Australia and New Zealand. Levels of evidence and grades of recommendation were assigned using the Grading of Recommendations Assessment, Development and Evaluation framework.

  • Open Access

    Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia

    by Raúl Córdoba, Stephan Stilgenbauer, Paolo Ghia, Alessandra Tedeschi, Lindsey Roeker, Myriam Rodriguez‐Couso, Stephen P. Mulligan, Samir Kanaan Nabhan, Jan Rynne, Teresa López‐Fernández

    Advancements in the understanding of chronic lymphocytic leukemia (CLL) have transformed patient care, leading to the development of novel targeted therapies. Traditionally, patient fitness for treatment was based on the tolerability of chemoimmunotherapy such as fludarabine–cyclophosphamide–rituximab. As the CLL patient population is predominantly older, age has historically been a major factor in how a physician selects a patient's treatment. However, as a patient's fitness goes beyond age, the definition of patient fitness should also evolve. Here, we provide suggestions for the current best practice on assessing fitness for treating CLL. Considerations for treatment include assessment of polypharmacy, history of infections, cardiovascular and renal comorbidities, functional status, cognitive and psychological status, nutritional status, and social support. The flow of assessments can start with a typical clinical evaluation followed by geriatric, cardiovascular, and renal reviews, if needed, and include collecting a patient's full history to evaluate their risk of complications with specific CLL treatments. The severity of a patient's cardiovascular profile can range from low to high risk; for those at high risk, collaboration with a cardiologist is recommended. Geriatric assessment is advised to determine baseline frailty and resilience to tolerate treatments, to avoid inappropriate treatment or undertreating patients based on chronological age, and to align the patient's fitness status with the most optimal treatment. Continuous monitoring and assessment, regardless of therapy, are recommended. Patient preferences are also integral to this decision‐making process. Looking beyond a patient's age and basing treatment selection on their fitness is key in the new era of treatment in CLL.


  • Open Access

    HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma

    by Elizabeth Hughes, Sue Latham, Bryone Kuss, Scott Grist, Rachel Hall, Tiffany Khong, Malgorzata Gorniak, Andrew Spencer, Constantine Tam, Stephen Mulligan, et al.

    The role of HAT-PCR (High A/T or High Annealing Temperature–PCR) in the quantification of minimal residual disease (MRD) was investigated in chronic lymphocytic leukemia (CLL) and myeloma. The IGH gene sequence was determined by next-generation sequencing (NGS), either by the Lymphotrack kit or by preparing libraries using an in-house two-round PCR protocol which enabled successful sequencing in 37/37 CLL marrow samples and 34/35 myeloma marrow samples. MRD was quantified by HAT-PCR in 125 CLL marrow or blood samples from 36 patients, with 2 results being less than 10−6 and in 63 myeloma marrow samples from 35 patients, with 10 results being less than 10−6. Measurement of MRD in 113 pairs of CLL samples and 51 pairs of myeloma samples showed that HAT-PCR was significantly more sensitive than flow. Compared to marrow MRD, blood MRD was relatively high in CLL but very low or undetectable in myeloma. Flow-positive HAT-PCR negative samples were not seen in myeloma, although the literature review suggested that flow-positive NGS-negative myeloma samples are sometimes observed. The ability of HAT-PCR to quantify down to and below 10−6 and the practical advantages of PCR suggest that HAT-PCR could be used widely for the quantification of MRD in lymphoid malignancy.


  • Open Access

    Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia

    by Stephen P. Mulligan, Philip A. Thompson, Joel Wight, Mary Ann Anderson, Sasanka M. Handunnetti, Andrea Puig, Steve Y. S. Su, Matthew J. Naylor

    The relapsed/refractory chronic lymphocytic leukemia treatment landscape has continued to evolve with Bruton's tyrosine kinase inhibitor (BTKi) emergence. Alongside extensive clinical trial results, real-world evidence for BTKi use in clinical practice is useful. Yet, published Australian real-world evidence is limited. This retrospective study describes ibrutinib and acalabrutinib use in the Australian real-world context, using data from December 2017 to August 2023 from the Pharmaceutical Benefits Scheme (PBS) 10% sample dataset. Acalabrutinib and ibrutinib were primarily dispensed in the second-line setting, corresponding to their PBS indications. Between agents, no statistically significant difference was seen in co-medication use or treatment persistence. Acalabrutinib treatment adherence was significantly higher than ibrutinib, despite similar treatment persistence. This may be attributed to dose reductions, unable to be captured by the PBS 10% dataset, which may have impacted ibrutinib adherence results. These data illustrate similar use and treatment persistence of acalabrutinib and ibrutinib in Australian clinical practice.


  • Open Access

    COVID-19 and CLL in Sweden: lessons learned?

    by Stephen P. Mulligan

  • An ALPINE guide to covalent BTKis in CLL

    by Stephen P. Mulligan

  • Open Access

    Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

    by Constantine S. Tam, Stephen Opat, Shirley D'SA, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García-Sanz, et al.

    The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on pretreatment bone marrow samples from 98 patients treated with zanubrutinib and 92 patients treated with ibrutinib with mutated (MUT) MYD88 and 20 patients with wild-type (WT) MYD88 treated with zanubrutinib. Of 329 mutations in 52 genes, mutations in CXCR4 (25.7%), TP53 (24.8%), ARID1A (15.7%), and TERT (9.0%) were most common. TP53MUT, ARID1AMUT, and TERTMUT were associated with higher rates of CXCR4MUT (P < .05). Patients with CXCR4MUT (frameshift or nonsense [NS] mutations) had lower very good partial response (VGPR) and complete response rates (CR; 17.0% vs 37.2%, P = .020) and longer time to response (11.1 vs 8.4 months) than patients with CXCR4WT treated with BTKis. CXCR4NS was associated with inferior progression-free survival (PFS; hazard ratio [HR], 3.39; P = .017) in patients treated with ibrutinib but not in those treated with zanubrutinib (HR, 0.67; P = .598), but VGPR + CR rates were similar between treatment groups (14.3% vs 15.4%). Compared with ibrutinib, patients with CXCR4NS treated with zanubrutinib had a favorable major response rate (MRR; 85.7% vs 53.8%; P = .09) and PFS (HR, 0.30; P = .093). In patients with TP53MUT, significantly lower MRRs were observed for patients treated with ibrutinib (63.6% vs 85.7%; P = .04) but not for those treated with zanubrutinib (80.8% vs 81.9%; P = .978). In TP53MUT, compared with ibrutinib, patients treated with zanubrutinib had higher VGPR and CR (34.6% vs 13.6%; P < .05), numerically improved MRR (80.8% vs 63.6%; P = .11), and longer PFS (not reached vs 44.2 months; HR, 0.66; P = .37). Collectively, patients with WM with CXCR4MUT or TP53MUT had worse prognosis compared with patients with WT alleles, and zanubrutinib led to better clinical outcomes.


  • Open Access

    Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

    by Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, et al.